)
Joel Edwards
CBO
Maxion Therapeutics
Joel joined Maxion as a Chief Business Officer in October 2025, bringing over 26 years of global experience in corporate strategy, operations, business development and alliance management, securing over $3.5 billion in strategic partnering revenue from pharmaceutical companies throughout his career.
Prior to joining Maxion, Joel served as CBO at Abilita Therapeutics and Biosion, closing major discovery collaborations and licensing transactions. He has held various leadership positions at Ionis Pharmaceuticals, playing key roles in the commercial launch of Kynamro, Spinraza, and Tegsedi and leading numerous strategic initiatives to build out Ionis' commercialization capabilities.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}